Top 10 High Tech Stocks For 2018

Universal Health Services (UHS) tumbled to the bottom of the S&P 500 today after BuzzFeed published an investigative story alleging that the company’s psychiatric hospitals put profits ahead of people.

Getty Images

Shares of Universal Health Services dropped 12% to$111.30 today, while the S&P 500 rose 1.3% to 2,241.35, a record high.

Universal Health Services’ stock had been minding its business for most of the day–it was up 1.1% at $127.76 at 3:10 p.m. today–when the story by BuzzFeed’s Rosalind Adams went live. Here’s the gist:

Millwood Hospital is part of Americas largest psychiatric hospital chain, Universal Health Services, or UHS. Its more than 200 psychiatric facilities across the country admitted nearly 450,000 patients last year. The result was almost $7.5 billion in revenues from inpatient care last year and profit margins of around 30%. More than a third of the companys overall revenue from both medical hospitals and psychiatric facilities comes from taxpayers through Medicare and Medicaid.

Top 10 High Tech Stocks For 2018: Fortress Investment Group LLC(FIG)

Advisors’ Opinion:

  • [By Dan Caplinger]

    The stock market continued to climb sharply on Wednesday, sending major market benchmarks to record highs yet again and propelling the Dow Jones Industrials up more than 100 points. Economic data continued to support the notion that the U.S. economy remains strong, and rising inflation levels led many to conclude that the Federal Reserve is more likely than ever to follow through on its promise to keep lifting short-term interest rates in 2017. Rising bond yields reflected investors’ reluctance to hold onto fixed-income investments in anticipation of higher rates, prompting some to shift assets into the stock market. Several companies also reported, andFortress Investment Group (NYSE:FIG), Editas Medicine (NASDAQ:EDIT), and Hertz Global Holdings (NYSE:HTZ) were among the top performers on the day. Below, we’ll look more closely at these stocks to tell you why they did so well.

Top 10 High Tech Stocks For 2018: USG Corporation(USG)

Advisors’ Opinion:

  • [By Stephan Byrd]

    ValuEngine upgraded shares of USG (NYSE:USG) from a buy rating to a strong-buy rating in a report published on Tuesday.

    A number of other research analysts have also recently weighed in on the stock. Credit Suisse Group upgraded shares of USG from an underperform rating to a neutral rating and dropped their target price for the company from $35.00 to $24.00 in a research note on Friday, April 27th. Jefferies Group reiterated a hold rating and issued a $40.00 target price on shares of USG in a research note on Monday, April 23rd. SunTrust Banks boosted their target price on shares of USG from $42.00 to $44.00 and gave the company a hold rating in a research note on Tuesday, April 17th. Buckingham Research boosted their target price on shares of USG from $34.00 to $42.00 and gave the company a neutral rating in a research note on Monday, April 16th. Finally, Nomura boosted their target price on shares of USG from $39.00 to $44.00 and gave the company a neutral rating in a research note on Tuesday, March 27th. Two investment analysts have rated the stock with a sell rating, ten have issued a hold rating, four have assigned a buy rating and one has given a strong buy rating to the stock. The stock currently has a consensus rating of Hold and an average price target of $39.00.

  • [By Jon C. Ogg]

    USG Corp. (NYSE: USG) was reiterated as Hold but the price target was raised to $35 from $29 (versus a $34.23 close) at Jefferies.

    Thursday’s top analyst upgrades and downgradesincluded Biogen, Goldcorp, GoPro, Oracle, Sirius XM, Tyson Foods, Ciena and many more.

  • [By Jordan Wathen]

    As USG Corporation (NYSE:USG) drags its feet on an offer to sell the company for $42 per share, Berkshire intends to use its 30.8% ownership stake to motivate its top brass to make a deal. Berkshire told Bloomberg it intends to vote its shares against USG’s board members who are up for re-election at this year’s annual meeting, a clear message that Buffett is ready to cash in, even if USG’s management and board are not.

  • [By The Ticker Tape]

    Homebuilders like Lennar, PulteGroup, Inc. (NYSE: PHM), and D.R. Horton, Inc. (NYSE: DHI) could benefit from a strengthening housing recovery. If you’re bullish on housing, you might want to take a step back and think about other companies in that space. Home improvement stores like Home Depot Inc (NYSE: HD) and Lowe's Companies, Inc. (NYSE: LOW) could get a boost as well as companies that supply products for new homes like Whirlpool Corporation (NYSE: WHR) and USG Corporation(NYSE: USG).

Top 10 High Tech Stocks For 2018: TESARO, Inc.(TSRO)

Advisors’ Opinion:

  • [By Todd Campbell]

    The PARP battle is on. Following news that AstraZeneca’s (NYSE:AZN) PARP-inhibiting cancer drug Lynparza delivered a big win in phase 3 studies, all eyes now shift to how a potential Food and Drug Administration approval for Lynparza will reshape the commercial opportunity for competitor Tesaro Inc. (NASDAQ:TSRO).

  • [By Ben Levisohn]

    Shares of Tesaro (TSRO) are soaring today after the biotech company reported positive data for its treatment of ovarian cancer over the weekend. Credit Suisse analyst Alethia Young and team contend that “M&A remains in focus” for Tesaro following the data:

    Getty Images

    We are increasing our target price to $122 from $90 as we move to an M&A DCF valuation. We were at ESMO this weekend, and we believe the big takeaway on Tesaro data is that it works broadly in all 2L ovarian populations and safety looks solid. We also think the robustness of this data bodes well from PRIMA and QUADRA but are maintaining our POS here. We have looked at our model and also adjusted durations in first-line. We think Tesaro remains one of the most attractive and de-risked cancer assets in our landscape and the company has been cited in major press sources as a takeout target (Bloomberg, Investor Business Daily).

    We think M&A remains in focus for Tesaro. Our M&A DCF valuations range from $122 to $157 by our model. We have also built models for other cancers like NSCLC, SCLC, prostate, and others where PARP might be impactful. We assume 0% POS for now but we conservatively see at least another $1B in sales from PARP expansion. Tesaro has been cited in the press as a potential M&A target and is a company we frequently hear mentioned as a target from our conversations. We think the demand for late stage oncology assets is high, especially in the PARP space given the potential for activity across a range of tumors. For a large Pharma player who already has an oncology salesforce and large R&D infrastructure we could see SG&A synergies of 50-75% and R&D synergies of 15-30%. In our base case TSRO P&L we model a tax rate of 30% so there could be synergies here as well. Two additional key swing factors which might be included in a CVR are how much expansion from PARP in other cancers and immuno-oncology…

    Ex M&A,

  • [By Ben Levisohn]

    Guggenheim’s Tony Butler and Kaitlin Sandor argue that Gilead Sciences (GILD) should buy Syndax Pharmaceuticals (SNDX), Corvus Pharmaceuticals (CRVS), and Tesaro (TSRO) to solve its problem of slowing sales:

  • [By Paul Ausick]

    Tesaro Inc. (NASDAQ: TSRO) traded down about 10% Tuesday and posted a new 52-week low of $74.57 after Friday at $82.87. The 52-week high is $192.94. Volume was about 2 million, more than double the daily average of around 870,000 million shares. The maker of cancer therapeutics had no specific news.

  • [By George Budwell]

    Unfortunately for Clovis and its shareholders, though, Astra’s Lynparza is currently underpriority review with the FDA as a maintenance therapy in ovarian cancer, andTesaro’s (NASDAQ:TSRO)rival PARP inhibitor Zejula gained an early approval– along with afar broader label than Rubraca — just this week.

  • [By Ben Levisohn]

    Look out below! Shares of Tesaro (TSRO) have dropped more than 10% this afternoon after AstraZeneca (AZN) released stronger-than-expected Phase 3 trial data on a its ovarian cancer treatment.

    Agence France-Presse/Getty Images

    The Street’sAdam Feuerstein has the details on AstraZeneca’s strong data and its impact on Tesaro:

    AstraZeneca’s (AZN) PARP inhibitor Lynparza delayed the recurrence of ovarian cancer by more than two years compared to a placebo, according to results from a phase III study presented Tuesday.

    The strong benefit observed with Lynparza as ovarian cancer maintenance therapy exceeded investor expectations and bolsters AstraZeneca against a competing PARP inhibitor from Tesaro (TSRO).

    Feuerstein also notes that AstraZeneca’s data could be good newsClovis Oncology (CLVS), which also had a PARP inhibitor approved recently, if it means that its drug could work as well as Astra’s.

    In February, Leerink cut Tesaro, arguing that the rally in its shares due to a potential takeover had run too far. Will it still be a takeover target?

    Shares of Tesaro have dropped 14% to $148.01 at 3:28 p.m. today, while AstraZeneca has gained 1.1% to $30.41, and Clovis Oncology has jumped 9.8% to$66.55.

    UPDATE:Piper Jaffray’sSteven Breazzano andJoshua Schimmer note that the AstraZeneca data shows that PARPs are “more similar than different.” They explain:

    This afternoon AstraZeneca (covered by PJC analyst Richard Purkiss) reported the detailed results from the SOLO-2 maintenance study of Lynparza in 2L+ ovarian cancer. The detailed data highlights a PFS benefit of 14 months (investigator assessed, and primary endpoint) and 25 months (blinded central review) over placebo, and favorable hazard ratio of 0.30 and 0.25, respectively, confirming our view that the PARP’s are more similar than different. As such, we believe this provides a favorable readth

Top 10 High Tech Stocks For 2018: Strayer Education, Inc.(STRA)

Advisors’ Opinion:

  • [By Joseph Griffin]

    These are some of the media headlines that may have impacted Accern Sentiment Analysis’s scoring:

    Get Strayer Education alerts:

    Form 4 STRAYER EDUCATION INC For: May 01 Filed by: MILANO TODD A (streetinsider.com) Q2 2018 Earnings Forecast for Strayer Education (STRA) Issued By Piper Jaffray (americanbankingnews.com) Strayer Education (STRA) Price Target Raised to $118.00 (americanbankingnews.com) Strayer Education (STRA) Q1 Earnings Beat, Enrollments Up (msn.com) Edited Transcript of STRA earnings conference call or presentation 2-May-18 2:00pm GMT (finance.yahoo.com)

    A number of brokerages recently weighed in on STRA. BidaskClub upgraded shares of Strayer Education from a “buy” rating to a “strong-buy” rating in a report on Wednesday, April 18th. BMO Capital Markets restated a “buy” rating and set a $107.00 target price on shares of Strayer Education in a report on Wednesday, April 11th. Piper Jaffray upgraded shares of Strayer Education from a “neutral” rating to an “overweight” rating in a report on Monday, March 5th. TheStreet cut shares of Strayer Education from a “b” rating to a “c+” rating in a report on Tuesday, March 13th. Finally, First Analysis upgraded shares of Strayer Education from an “equal weight” rating to an “overweight” rating and raised their target price for the stock from $105.00 to $112.00 in a report on Sunday, March 4th. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the company. Strayer Education presently has an average rating of “Buy” and an average price target of $106.50.

  • [By Lisa Levin]

    Shares of Capella Education Company (NASDAQ: CPLA) got a boost, shooting up 32 percent to $86.60. Strayer Education Inc (NASDAQ: STRA) and Capella Education agreed to an all-stock merger. Capella Education also posted upbeat quarterly earnings.

  • [By Lisa Levin]

    In trading on Thursday, non-cyclical consumer goods & services shares fell by 1.21 percent. Meanwhile, top losers in the sector included Strayer Education Inc (NASDAQ: STRA), down 13 percent, and MGP Ingredients Inc (NASDAQ: MGPI), down 6 percent.

Top 10 High Tech Stocks For 2018: Ascent Capital Group, Inc.(ASCMA)

Advisors’ Opinion:

  • [By Ian Wyatt, Publisher & Chief Investment Strategist, Wyatt Investment Research]

    Both of these stocks are overlooked, undervalued, and cash flow machines. The companies are Ascent Capital Group (ASCMA) and Covanta Holdings (CVA).

  • [By Lisa Levin]

    Tuesday afternoon, the industrial sector proved to be a source of strength for the market. Leading the sector was strength from NL Industries Inc (NYSE: NL) and Ascent Capital Group Inc (NASDAQ: ASCMA).

Top 10 High Tech Stocks For 2018: Euronav NV(EURN)

Advisors’ Opinion:

  • [By Lisa Levin]

    Check out these big penny stock gainers and losers

    Losers
    Teradyne, Inc. (NYSE: TER) fell 10.8 percent to $37.02 in pre-market trading after the company issued downbeat Q2 guidance.
    Edwards Lifesciences Corporation (NYSE: EW) fell 9.2 percent to $122.29 in pre-market trading. Edwards Lifesciences reported better-than-expected results for its first quarter, but issued weak earnings guidance for the second quarter.
    New Gold Inc. (NYSE: NGD) fell 8.8 percent to $2.30 in pre-market trading after rising 4.13 percent on Tuesday.
    Gold Fields Limited (ADR) (NYSE: GFI) fell 8.6 percent to $3.61 in pre-market trading.
    Natus Medical Incorporated (NASDAQ: BABY) fell 8.2 percent to $32.95 in pre-market trading after the company issued weak forecast for the second quarter.
    Atossa Genetics Inc. (NASDAQ: ATOS) shares fell 7.9 percent to $3.50 in pre-market trading after climbing 27.09 percent on Tuesday.
    Bright Scholar Education Holdings Limited (NYSE: BEDU) shares fell 6.7 percent to $13.58 in pre-market trading after reporting Q1 results.
    Sangamo Therapeutics Inc (NASDAQ: SGMO) fell 5.9 percent to $16.75 in pre-market trading following announcement of a $200 million common stock offering.
    Foresight Autonomous Holdings Ltd (NASDAQ: FRSX) shares fell 5.7 percent to $3.29 in pre-market trading after declining 3.32 percent on Tuesday.
    Euronav NV (NYSE: EURN) fell 4.8 percent to $8.40 in pre-market trading.
    Limelight Networks, Inc. (NASDAQ: LLNW) shares fell 4.3 percent to $4.69 in pre-market trading.
    Gaming and Leisure Properties Inc (NASDAQ: GLPI) shares fell 4.1 percent to $32.92 in pre-market trading after the company issued downbeat quarterly results and reported the retirement of CFO William Clifford

Top 10 High Tech Stocks For 2018: Citrix Systems Inc.(CTXS)

Advisors’ Opinion:

  • [By Ben Levisohn]

    Wynn Resortsgained 4.8% to $104.30 today, while the S&P 500 finished little changed at2,373.47. At 2:45, Wynn was easily the top performing stock in the S&P 500, only to be surpassed by Citrix’s (CTXS) late day surge.

  • [By Chris Lange]

    The stock posting the largest daily percentage gain in the S&P 500 ahead of the close Monday was Citrix Systems, Inc. (NASDAQ: CTXS) which jumped 6.8% to $84.93. The stocks 52-week range is $59.72 to $87.99. Volume was 5.19 million which is well above the daily average of around 2.09 million shares.

  • [By Jim Robertson]

    At the beginning of the month, LogMeIn announced the completion of its merger with Citrix Systems, Inc (NASDAQ: CTXS) GetGo, Inc subsidiary.

    In late October, LogMeIn reported 22% third quarter revenue growth to $85.1 million and GAAP net loss was $0.7 million compared to a GAAP net income of $5.6 million. LogMeIn will report its fourth quarter and fiscal year 2016 financial results for the period ended December 31, 2016 following the close of market on February 28.

Top 10 High Tech Stocks For 2018: National Steel Corporation(SID)

Advisors’ Opinion:

  • [By Lisa Levin]

    Basic materials shares climbed by 1.52 percent in trading on Friday. Meanwhile, top gainers in the sector included Companhia Siderurgica Nacional (ADR) (NYSE: SID), and Core Molding Technologies, Inc. (NYSE: CMT).

Top 10 High Tech Stocks For 2018: Exelon Corporation(EXC)

Advisors’ Opinion:

  • [By Monica Gerson]

    Analysts are expecting Exelon Corporation (NYSE: EXC) to have earned $0.68 per share on revenue of $7.52 billion in the latest quarter. Exelon shares rose 0.34 percent to close at $35.38 on Thursday.

  • [By Horizon Investments]

    For the past year, Exelon Corp. (EXC) has had a roller coaster ride, with the stock having plummeted 15% since September 2012 – the company had announced a dividend cut of 41%, which led to a drop in the share price. Separately, the recent weak PJM auction prices did not bode well for the company. However, I believe the worst is priced in the stock price, and the company’s management is committed to improving its financial flexibility and cost structure in order to strengthen its financial performance. Also, the company is planning to incur capital expenditure (CAPEX) in the upcoming years, which will result in rate base growth for Exelon.

  • [By Lisa Levin]

    Utilities shares climbed by 0.64 percent in trading on Friday. Meanwhile, top gainers in the sector included Exelon Corporation (NYSE: EXC), and FirstEnergy Corp. (NYSE: FE).

Top 10 High Tech Stocks For 2018: WD-40 Company(WDFC)

Advisors’ Opinion:

  • [By Monica Gerson]

    WD-40 Company (NASDAQ: WDFC) is projected to post its quarterly earnings at $0.86 per share on revenue of $99.10 million.

    Hooker Furniture Corporation (NASDAQ: HOFT) is estimated to report its quarterly earnings at $0.40 per share on revenue of $62.20 million.

  • [By Monica Gerson]

    WD-40 Company (NASDAQ: WDFC) reported better-than-expected earnings for its second quarter, but the company missed analysts’ sales estimates. WD-40 shares fell 0.97 percent to $106.00 in the after-hours trading session.